We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
- Authors
Carter, Bing Z.; Po Yee Mak; Hong Mu; Hongsheng Zhou; Mak, Duncan H.; Schober, Wendy; Leverson, Joel D.; Bin Zhang; Bhatia, Ravi; Xuelin Huang; Cortes, Jorge; Kantarjian, Hagop; Konopleva, Marina; Andreeff, Michael
- Abstract
The article discusses research which focused on the concomitant targeting of B-cell lymphoma 2 (BCL-2) and breakpoint cluster region protein (BCR)-Abelson murine leukemia viral oncogene homolog 1 (ABL) tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML). Topics explored include the role of BCR-ABL TKI in molecular therapies, the antileukemic activity observed in transgenic mice models of BCR-ABL, and brief details on the identification and treatment of CML cells.
- Subjects
BCL-2 proteins; ABL1 gene; PROTEIN-tyrosine kinase inhibitors; CHRONIC myeloid leukemia; THERAPEUTICS research
- Publication
Science Translational Medicine, 2016, Vol 8, Issue 355, p1
- ISSN
1946-6234
- Publication type
Article
- DOI
10.1126/scitranslmed.aag1180